State Street

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Thursday, March 7, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Janus, Attention, Prospectus, Medicine, Capital market, MindMed, Telephone, RBC Capital Markets, File, Cantor, Sale, Form, Richard Driehaus, State Street, SVB Securities, Security (finance)

In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.

Key Points: 
  • In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.
  • Gross proceeds to MindMed from the underwritten offering and concurrent private placement, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million.
  • Leerink Partners and Cantor are acting as joint bookrunning managers for the underwritten offering and placement agents for the private placement.
  • RBC Capital Markets is acting as lead manager for the underwritten offering and placement agent for the private placement.

Easterly Asset Management Appoints BlackRock’s Phil Juliano, Jr. as Head of Sales

Retrieved on: 
Wednesday, March 6, 2024
Asset Management, Professional Services, Finance, Fidelity, Growth, UBS, Index, Business development, State Street, Affiliation, BlackRock, IShares, FINRA, ETP, MSCI, Partnership, Financial adviser

Easterly Asset Management (“Easterly”), a multi-affiliate platform for high-performing boutique investment firms, announced the appointment of Phil (PJ) Juliano, Jr. as its Head of Sales.

Key Points: 
  • Easterly Asset Management (“Easterly”), a multi-affiliate platform for high-performing boutique investment firms, announced the appointment of Phil (PJ) Juliano, Jr. as its Head of Sales.
  • “Easterly is on a mission to connect all client types with comprehensive investment managers and solutions,” said Mr. Juliano.
  • Darrell Crate, Founder and Managing Principal of Easterly, said, “Phil brings unparalleled expertise in holistic value creation for investment managers.
  • He was an executive member of the iShares Institutional team setting sales strategy, business planning, talent management and budget.

Sidus Space Announces Closing of Public Offering

Retrieved on: 
Tuesday, March 5, 2024
Mobile, Wireless, Technology, Engineering, Satellite, Telecommunications, Aerospace, Manufacturing, Internet, Hardware, Data Management, ThinkEquity, Sidus, State Street, Prospectus, Sale, Life insurance

Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced the closing of its previously announced public offering of 1,321,000 shares of its Class A common stock at a public offering price of $6.00 per share for gross proceeds of $7,926,000, before deducting underwriting discounts and offering expenses.

Key Points: 
  • Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced the closing of its previously announced public offering of 1,321,000 shares of its Class A common stock at a public offering price of $6.00 per share for gross proceeds of $7,926,000, before deducting underwriting discounts and offering expenses.
  • The Company intends to use the proceeds from the offering for working capital and general corporate purposes.
  • ThinkEquity acted as sole book-running manager for the offering.
  • The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov .

Oragenics Announces Closing of Public Offering

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, ThinkEquity, State Street, DSM-IV codes, Prospectus, Sale, Concussion, Life insurance

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts, and offering expenses payable by the Company.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts, and offering expenses payable by the Company.
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 210,000 shares of its common stock at the public offering price, less discounts, to cover over-allotments, if any.
  • ThinkEquity and Laidlaw & Company (UK) Ltd. acted as joint book-running managers for the offering.
  • The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov .

State Street Announces $100 Million Program for Minority Depository Institutions and Community Development Financial Institutions

Retrieved on: 
Thursday, February 29, 2024
Professional Services, Communications, Finance, Asset Management, Banking, Public Relations, Investor Relations, MLT, Community development, Certification, Racism, Workplace, Mechanics, Growth, State Street Corporation, Address, State Street, STT, State, Inequality, Partnership

State Street Corporation (NYSE: STT) today announced a $100 million program to provide low-cost, stable deposit funding to minority depository institutions (MDIs)1 and Community Development Financial Institutions (CDFIs)2, to support the firms’ collective missions of addressing inequities in our communities by working toward a more just and equitable future.

Key Points: 
  • State Street Corporation (NYSE: STT) today announced a $100 million program to provide low-cost, stable deposit funding to minority depository institutions (MDIs)1 and Community Development Financial Institutions (CDFIs)2, to support the firms’ collective missions of addressing inequities in our communities by working toward a more just and equitable future.
  • As a part of this program, the firm is initially partnering with two mission-driven MDIs - Optus Bank and Mechanics & Farmers Bank (M&F Bank).
  • Both MDIs and CDFIs support low-to-moderate income communities through lending, affordable housing and workforce development.
  • This program, builds upon State Street’s actions to advance racial equity.

Sidus Space Announces Pricing of Public Offering

Retrieved on: 
Friday, March 1, 2024
Software, Mobile, Wireless, Hardware, Data Management, Technology, Other Manufacturing, Satellite, Engineering, Aerospace, Other Technology, Manufacturing, Telecommunications, ThinkEquity, S-3, Sidus, State Street, Prospectus, Sale, Form

Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced the pricing of an underwritten public offering of 1,321,000 shares of its Class A common stock.

Key Points: 
  • Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced the pricing of an underwritten public offering of 1,321,000 shares of its Class A common stock.
  • Each share of Class A common stock is being sold at a public offering price of $6.00 per share for gross proceeds of approximately $7.9 million, before deducting underwriting discounts and offering expenses.
  • The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
  • A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov .

Sidus Space Announces Proposed Public Offering

Retrieved on: 
Thursday, February 29, 2024
Technology, Mobile, Wireless, Engineering, Satellite, Telecommunications, Aerospace, Manufacturing, Internet, Data Management, ThinkEquity, S-3, Sidus, State Street, Prospectus, Sale, Warrant, Form

Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced that it intends to offer to sell shares of its Class A common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering.

Key Points: 
  • Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced that it intends to offer to sell shares of its Class A common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering.
  • ThinkEquity is acting as sole book-running manager for the offering.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Oragenics Announces Proposed Public Offering

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Neurology, Infectious Diseases, Health, Pharmaceutical, ThinkEquity, Prospectus, Concussion, Sale, Form, State Street, S-3, DSM-IV codes, Security (finance)

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants to purchase shares of common stock (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants to purchase shares of common stock (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • ThinkEquity and Laidlaw & Company (UK) Ltd. are acting as joint book-running managers for the offering.
  • The offering will be made only by means of a written prospectus.

Oragenics Announces Pricing of Public Offering

Retrieved on: 
Wednesday, February 28, 2024
Health, Infectious Diseases, Neurology, General Health, Pharmaceutical, Biotechnology, ThinkEquity, S-3, Security (finance), State Street, DSM-IV codes, Sale, Form, Concussion, Life insurance

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts and offering expenses payable by the Company.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts and offering expenses payable by the Company.
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 210,000 shares of its common stock at the public offering price, less discounts, to cover over-allotments, if any.
  • The offering is expected to close on March 1, 2024, subject to satisfaction of customary closing conditions.
  • ThinkEquity and Laidlaw & Company (UK) Ltd. are acting as joint book-running managers for the offering.

MarketAxess Appoints Ilene Fiszel Bieler as Chief Financial Officer

Retrieved on: 
Monday, February 26, 2024
Finance, Professional Services, Technology, Fintech, Software, Barclays, Citigroup, Growth, MarketAxess, State Street, University, History, Executive, Head, Partnership, Management

MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, today announced the appointment of Ilene Fiszel Bieler as Chief Financial Officer.

Key Points: 
  • MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, today announced the appointment of Ilene Fiszel Bieler as Chief Financial Officer.
  • Ms. Fiszel Bieler is currently expected to start with MarketAxess on or about May 22, 2024.
  • Ms. Fiszel Bieler replaces Christopher Gerosa, who left the Company on January 31, 2024.
  • “MarketAxess is an S&P500 company with a remarkable history of over two decades of innovation and leadership in the fixed-income space,” said Ms. Fiszel Bieler.